Skip to content

Ketamine for addiction: all studies

Page 10 of 15: studies 91 to 100 of 144, newest first. Back to the ketamine for addiction overview

Research

Historical Pathways for Opioid Addiction, Withdrawal with Traditional and Alternative Treatment Options with Ketamine, Cannabinoids, and Noribogaine: A Narrative Review

Health Psychology Research October 6, 2022 Amber N. Edinoff, Natalie W. Wu, Bryce Bonin et al. 11 citations

Even as prescription opioid dispensing rates have begun to decrease, the use of illicit opioids such as heroin and fentanyl has increased. Thus, the end of the opioid epidemic is not in sight, and treating patients that are addicted to opioids remains of utmost importance. Currently, the primary pharmacotherapies used to treat opioid addiction over the long term are the opioid antagonist...

DOI: 10.52965/001c.38672 (opens in new tab) Full text (opens in new tab) Ketamine Narrative review Opioid addiction Psychotherapist +1

Ketamine-Induced Cystitis: A Comprehensive Review of the Urologic Effects of This Psychoactive Drug.

Health Psychology Research September 15, 2022 Danyon J Anderson, Jessica Zhou, David Cao et al.

Ketamine is a common medical anesthetic and analgesic but is becoming more widely used as a recreational drug. Significant side effects on the urinary tract are associated with frequent recreational ketamine use most notably ketamine-induced cystitis (KIC). Regular ketamine consumption has been shown to increase the risk of cystitis symptoms by 3- to 4-fold, and cessation of ketamine use is...

Sex dependence of opioid-mediated responses to subanesthetic ketamine

bioRxiv Preprint Server September 6, 2022 Tommaso Di Ianni, Matine M. Azadian, Sedona N. Ewbank et al. 2 citations preprint

Subanesthetic ketamine rapidly and robustly reduces depressive symptoms in patients with treatment-resistant depression. While it is commonly classified as an N-methyl D-aspartate receptor (NMDAR) antagonist, our picture of ketamine’s mechanistic underpinnings is incomplete. Recent clinical evidence has indicated, controversially, that a component of the efficacy of ketamine in depression may...

DOI: 10.1101/2022.09.06.506854 (opens in new tab) Full text (opens in new tab) Esketamine Rapid-acting antidepressant Sex differences Gender differences +17

Efficacy of ketamine intervention to decrease alcohol use, cravings, and withdrawal symptoms in adults with problematic alcohol use or alcohol use disorder: A systematic review and comprehensive analysis of mechanism of actions.

Drug and Alcohol Dependence August 19, 2022 Nicolas Garel, Christina Mcanulty, Kyle T. Greenway et al. 33 citations

BACKGROUND: Alcohol use disorder is highly prevalent and has important economical, societal, psychiatric, and medical consequences. All currently approved therapeutic approaches targeting alcohol dependence have relatively modest effects and high relapse rates. Recent evidence suggests that ketamine may be an effective intervention to treat alcohol use disorder and alcoholic withdrawal. This...

D-cycloserine (DCS) is Not Susceptible to Self-administration, unlike S-ketamine Using an Intravenous Self-administration Model in Naive and Ketamine-habituated Sprague-Dawley Rats

bioRxiv Preprint Server August 12, 2022 Daniel C Javitt, Jonathan C. Javitt preprint

OBJECTIVE N-methyl D-aspartate Receptor (NMDAR) antagonist antidepressants have known potential for abuse liability. The aim of this study was to evaluate the abuse liability of D-cycloserine (DCS), using a self-administration paradigm in which DCS was tested in its efficacy in substituting for ketamine in ketamine-dependent rats.

DOI: 10.1101/2022.08.12.503713 (opens in new tab) Full text (opens in new tab) D-cycloserine Dcs Low abuse potential Non-addictive +13

Dual action of ketamine confines addiction liability.

Nature August 2022 Linda D. Simmler, Yue Li, Lotfi C Hadjas et al.

Ketamine is used clinically as an anaesthetic and a fast-acting antidepressant, and recreationally for its dissociative properties, raising concerns of addiction as a possible side effect. Addictive drugs such as cocaine increase the levels of dopamine in the nucleus accumbens. This facilitates synaptic plasticity in the mesolimbic system, which causes behavioural adaptations and eventually...

Ketamine As A New Therapeutic Option For The Management Of Mental Disorders

European Psychiatry June 1, 2022 M. Turki, O. Abidi, S. Ellouze et al. 1 citation

Introduction Ketamine is routinely used for anesthetic induction because of its dissociative properties. Recently, it has attracted attention as a rapid-acting anti-depressant, but other studies have also reported its efficacy in the management of diverse psychiatric pathologies previously resistant to treatment. Objectives We aimed to review the efficacity of ketamine in the management of...

Adjunctive Ketamine With Relapse Prevention-Based Psychological Therapy in the Treatment of Alcohol Use Disorder

March 25, 2022

Ketamine plus mindfulness psychotherapy was more effective for sustained abstinence from alcohol than placebo plus alcohol psychoeducation. Other combinations of these therapies were not significantly different from one another in this small pilot trial (N=20-25 in each group). Adverse effects were minimal, suggesting that current alcohol use is not a contraindication for consideration of...

Non-parenteral Ketamine for Depression: A Practical Discussion on Addiction Potential and Recommendations for Judicious Prescribing

CNS Drugs February 14, 2022 Jennifer Swainson, L. Klassen, Stefan Brennan et al. 42 citations

Intravenous (IV) ketamine is increasingly used off-label at subanesthetic doses for its rapid antidepressant effect, and intranasal (IN) esketamine has been recently approved in several countries for treating depression. The clinical utility of these treatments is limited by a paucity of publicly funded IV ketamine and IN esketamine programs and cost barriers to private treatment programs, as...

Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review - CORRIGENDUM.

BJPsych Open January 18, 2022 Zach Walsh, Özden Merve Mollaahmetoğlu, Joseph M. Rootman et al. 28 citations

An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the ‘Save PDF’ action button.

DOI: 10.1192/bjo.2022.5 (opens in new tab) Full text (opens in new tab) Ketamine therapy Ketamine treatment Ketamine application Ketamine use +12